✦ LIBER ✦

P118 Preliminary results of HOPLITE trial, a factorial phase II randomized trial of continuous (C) or intermittent (I) docetaxel (D) ± estramustine (E) as first line treatment for castration resistant prostate cancer (CRPC)

✍ Scribed by Caffo, O.; Lo Re, G.; Sava, T.; Buti, S.; Sacco, C.; Basso, U.; Zustovich, F.; Martini, T.; Perin, A.; Veccia, A.; Russo, L.M.; Facchini, G.; Barile, C.; Gernone, A.; De Vivo, R.; Pappagallo, G.; Galligioni, E.

Book ID: 122691880
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 72 KB
Volume: 11
Category: Article
ISSN: 1569-9056
DOI: 10.1016/S1569-9056(13)60484-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

305 RESULTS OF A MULTICENTRIC PHASE II R

305 RESULTS OF A MULTICENTRIC PHASE II RANDOMIZED TRIAL WITH DOCETAXEL (D) ± ESTRAMUSTINE (E) AS FIRST LINE CHEMOTHERAPY FOR PATIENTS (PTS) WITH HORMONE-REFRACTORY ADVANCED PROSTATE CANCER (HRPC)

✍ O. Caffo; E. Comploj; T. Sava; G. Mansueto; F. Zustovich; R. Segati; C. Sacco; A 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 316 KB

565 POSTER Activity of the anti-IGF-IR a

565 POSTER Activity of the anti-IGF-IR antibody CP-751,871 in combination with docetaxel as first-line treatment for castration resistant prostate cancer in a randomized Phase II trial

✍ J.S. De Bono; D.P. Petrylak; E. Calvo; F. Saad; G.R. Hudes; M.M. Cooney; M.N. Po 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

P-463 Preliminary results of a multicent

P-463 Preliminary results of a multicenter randomized phase II trial oftwo different combinations of docetaxel (D) and gemcitabine (G) and of cisplatin/gemcitabine (CG) followed by docetaxel as first line therapy for locally advanced or metastatic non small cell lung cancer (NSCLC)

✍ Bernardini, I.; Rinaldi, M.; Crinò, L.; Nardi, M.; De Marinis, F.; Tonato, M.; S 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 130 KB